Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 4
2001 4
2002 4
2003 1
2004 1
2005 2
2006 7
2007 1
2008 5
2009 5
2010 5
2011 8
2012 3
2013 10
2014 13
2015 10
2016 9
2017 6
2018 16
2019 18
2020 25
2021 23
2022 19
2023 20
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

203 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
Shi Q, Wang Y, Hao Q, Vandvik PO, Guyatt G, Li J, Chen Z, Xu S, Shen Y, Ge L, Sun F, Li L, Yu J, Nong K, Zou X, Zhu S, Wang C, Zhang S, Qiao Z, Jian Z, Li Y, Zhang X, Chen K, Qu F, Wu Y, He Y, Tian H, Li S. Shi Q, et al. Lancet. 2022 Jan 15;399(10321):259-269. doi: 10.1016/S0140-6736(21)01640-8. Epub 2021 Dec 8. Lancet. 2022. PMID: 34895470 Retracted and republished. Retracted.
High to moderate certainty evidence established phentermine-topiramate as the most effective in lowering weight (odds ratio [OR] of 5% weight reduction 8.02, 95% CI 5.24 to 12.27; mean difference [MD] of percentage bodyweight change -7.97, 95% CI -9.28 to -6.66) followed by GLP-1 …
High to moderate certainty evidence established phentermine-topiramate as the most effective in lowering weight (odds ratio [OR] of 5% weigh …
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Khera R, et al. JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001/jama.2016.7602. JAMA. 2016. PMID: 27299618 Free PMC article. Review.
Compared with placebo, liraglutide (OR, 2.95; 95% CrI, 2.11-4.23) and naltrexone-bupropion (OR, 2.64; 95% CrI, 2.10-3.35) were associated with the highest odds of adverse event-related treatment discontinuation. ...CONCLUSIONS AND RELEVANCE: Among overweight or obese adult …
Compared with placebo, liraglutide (OR, 2.95; 95% CrI, 2.11-4.23) and naltrexone-bupropion (OR, 2.64; 95% CrI, 2.10-3.35) were associ …
Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.
Kim PS, Fishman MA. Kim PS, et al. Curr Pain Headache Rep. 2020 Aug 26;24(10):64. doi: 10.1007/s11916-020-00898-0. Curr Pain Headache Rep. 2020. PMID: 32845365
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose naltrexone in the treatment of chronic pain. RECENT FINDINGS: Recent pre-clinical uses and clinical studies further elucidate the use of low-d …
PURPOSE OF REVIEW: The purpose of this review is to evaluate and explain our current understanding of the clinical use of low-dose naltre …
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
McPheeters M, O'Connor EA, Riley S, Kennedy SM, Voisin C, Kuznacic K, Coffey CP, Edlund MD, Bobashev G, Jonas DE. McPheeters M, et al. JAMA. 2023 Nov 7;330(17):1653-1665. doi: 10.1001/jama.2023.19761. JAMA. 2023. PMID: 37934220
The numbers needed to treat to prevent 1 person from returning to any drinking were 11 (95% CI, 1-32) for acamprosate and 18 (95% CI, 4-32) for oral naltrexone at a dose of 50 mg/d. Compared with placebo, oral naltrexone (50 mg/d) was associated with lower rates of …
The numbers needed to treat to prevent 1 person from returning to any drinking were 11 (95% CI, 1-32) for acamprosate and 18 (95% CI, 4-32) …
Pharmacotherapy of impulse control disorders: A systematic review.
Tahir T, Wong MM, Maaz M, Naufal R, Tahir R, Naidoo Y. Tahir T, et al. Psychiatry Res. 2022 May;311:114499. doi: 10.1016/j.psychres.2022.114499. Epub 2022 Mar 7. Psychiatry Res. 2022. PMID: 35305343 Review.
Importantly, divalproex was not superior to placebo in decreasing IED symptoms and was associated with significant adverse effects. In the treatment of kleptomania, only naltrexone was effective. The existing data suggest that the pharmacological treatment for impulse cont …
Importantly, divalproex was not superior to placebo in decreasing IED symptoms and was associated with significant adverse effects. In the t …
Treating nonsuicidal self-injury: a systematic review of psychological and pharmacological interventions.
Turner BJ, Austin SB, Chapman AL. Turner BJ, et al. Can J Psychiatry. 2014 Nov;59(11):576-85. doi: 10.1177/070674371405901103. Can J Psychiatry. 2014. PMID: 25565473 Free PMC article. Review.
RESULTS: Several interventions appear to hold promise for reducing NSSI, including dialectical behaviour therapy, emotion regulation group therapy, manual-assisted cognitive therapy, dynamic deconstructive psychotherapy, atypical antipsychotics (aripiprazole), naltrexone, …
RESULTS: Several interventions appear to hold promise for reducing NSSI, including dialectical behaviour therapy, emotion regulation group t …
Naltrexone-bupropion (Mysimba) in management of obesity: A systematic review and meta-analysis of unpublished clinical study reports.
Onakpoya IJ, Lee JJ, Mahtani KR, Aronson JK, Heneghan CJ. Onakpoya IJ, et al. Br J Clin Pharmacol. 2020 Apr;86(4):646-667. doi: 10.1111/bcp.14210. Epub 2020 Feb 4. Br J Clin Pharmacol. 2020. PMID: 31918448 Free PMC article. Review.
Naltrexone-bupropion had significantly beneficial effects on other cardiovascular risk factors; however, the true effect sizes for these are uncertain because of incomplete outcome data. ...CONCLUSIONS: Naltrexone-bupropion significantly reduces body weight by a sma …
Naltrexone-bupropion had significantly beneficial effects on other cardiovascular risk factors; however, the true effect sizes for th …
Combined Pharmacotherapy and Cognitive Behavioral Therapy for Adults With Alcohol or Substance Use Disorders: A Systematic Review and Meta-analysis.
Ray LA, Meredith LR, Kiluk BD, Walthers J, Carroll KM, Magill M. Ray LA, et al. JAMA Netw Open. 2020 Jun 1;3(6):e208279. doi: 10.1001/jamanetworkopen.2020.8279. JAMA Netw Open. 2020. PMID: 32558914 Free PMC article.
The mean (SD) age of the patient sample was 39 (6) years, with a mean (SD) of 28% (12%) female participants per study. The following pharmacotherapies were used: naltrexone hydrochloride and/or acamprosate calcium (26 of 62 effect sizes [42%]), methadone hydrochloride or c …
The mean (SD) age of the patient sample was 39 (6) years, with a mean (SD) of 28% (12%) female participants per study. The following pharmac …
A systematic review of licensed weight-loss medications in treating antipsychotic-induced weight gain and obesity in schizophrenia and psychosis.
Lee K, Abraham S, Cleaver R. Lee K, et al. Gen Hosp Psychiatry. 2022 Sep-Oct;78:58-67. doi: 10.1016/j.genhosppsych.2022.07.006. Epub 2022 Jul 14. Gen Hosp Psychiatry. 2022. PMID: 35863294 Free article. Review.
METHOD: A literature search was conducted using Medline, EMBASE, PsycINFO and Cochrane Library online databases for human studies using licensed WLMs to treat AIWG and OSP. RESULTS: Three RCTs (two liraglutide, one naltrexone-bupropion), one unpublished open-label trial ( …
METHOD: A literature search was conducted using Medline, EMBASE, PsycINFO and Cochrane Library online databases for human studies using lice …
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.
Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Siefried KJ, et al. CNS Drugs. 2020 Apr;34(4):337-365. doi: 10.1007/s40263-020-00711-x. CNS Drugs. 2020. PMID: 32185696 Free PMC article.
The most consistent positive findings have been demonstrated with stimulant agonist treatment (dexamphetamine and methylphenidate), naltrexone and topiramate. Less consistent benefits have been shown with the antidepressants bupropion and mirtazapine, the glutamatergic age …
The most consistent positive findings have been demonstrated with stimulant agonist treatment (dexamphetamine and methylphenidate), naltr …
203 results